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Abstract 
 
The site-specific treatment of cancer can reduce the toxic side effects of chemotherapy. 
This thesis reviews current techniques and describes a nanotechnology approach to 
investigate some of the obstacles in site-specific drug targeting and activation. One site-
specific approach is antibody-directed enzyme prodrug therapy, ADEPT. For this 
strategy, a targeting antibody directed against a tumor antigen is connected to an 
activating enzyme. For this project, -glucuronidase was selected as the activating 
enzyme and glucuronide prodrugs, of known highly potent chemotherapeutic agents, 
were selected as enzyme substrates. Prodrug-activating enzymes localizing exclusively at 
a tumor site, with tumor-specific targeting nanoparticles, minimizes the exposure of 
active chemotherapeutic agents. Because of the inactivity of glucuronide prodrugs, this 
treatment does not kill healthy cells.     
 This thesis reviews current techniques on glucuronide production and is a description of 
a -glucuronidase immobilization in nanoparticles procedure that investigates some of 
the obstacles in site-specific drug activation. Chapter I is an introduction to glucuronides, 
the glucuronidation procedure, and enzyme immobilization. Chapter II is a description of 
the glucuronidation of 4-nitrophenol, epirubicin, and homoharringtonine. It begins with 
the synthesis of 4-nitrophenyl-glucuronide. 4-Nitrophenol is a classic substrate for 
glucuronidation, is easy to prepare, and was used to evaluate the conditions for 
glucuronide formation and cleavage with -glucuronidase in nanoparticles. Formation of 
free p-nitrophenol was determined by HPLC with UV detection.   
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Homoharringtonine (HHT, Omacetine, Synribo), a highly potent chemotherapy agent, 
was initially chosen for an anti-cancer glucuronide prodrug for activation with -
glucuronidase embedded in nanoparticles. HHT’s aliphatic alcohol may be conjugated 
with -D-glucuronic acid, either by chemical or biosynthetic methods, to produce the 
desired glucuronide. A glucuronide of Homoharringtonine has not been reported in 
literature and its production is of interest for researchers to pharmaceutically evaluate a 
new anti-cancer glucuronide prodrug. Since HHT is such a potent cancer drug, it would 
be of interest to compare the cleavage of HHT-glucuronide by -glucuronidase to a well-
studied compound such as epirubicin glucuronide; that has been evaluated as ADEPT 
stragety.     
Unfortunately, synthetic methods ( the Koenig-Knorr reaction, failed to produce the 
desired HHT-glucuronide. Consequently, experiments with -glucuronidase entrapped-
nanoparticles were conducted with p-nitrophenol glucuronide and epirubicin glucuronide. 
When preparations of a glucuronide of HHT fail, due to steric hindrance, epirubicin is 
chosen as an alternative. Epirubicin glucuronide is mostly not activated by -
glucuronidase endogenous in microbial bio-flora within humans or naturally produced -
glucuronidase within human liver and other tissues (Hasima, H.J.,et al. 1992). Lack of 
promiscuity in glucuronide cleavage is possible to be beneficial in retaining site-specific 
activation. The production of epirubicin glucuronide is catalyzed by the human enzyme 
UDP-Glucuronosyltransferase 2B7 (UGT 2B7), in the liver (Innocenti, F., et al 2001). 
Toxic side effects of chemotherapeutic drugs are overcome with their glucuronides by 
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localizing activity to a target tumor site with the activating enzyme encapsulated in a 
nanoparticle, invivo. After biosynthesis and HPLC purification of the anti-cancer 
glucuronide prodrug epirubicin glucuronide, cleavage by β-Glucuronidase was tested in-
vitro. A large amount of enzyme (100 U/ml of glucuronidase in 4mM phosphate buffer 
pH=6.8) is needed to activate the prodrug. An added benefit of protein encapsulation is to 
prevent proteins being recognized as foreign invivo and consequently degraded.  
In Chapter III, a suitable polymer for encapsulation of glucuronidase is alginic acid cross-
linked with the addition of calcium ions, displacing sodium, forming alginate 
nanoparticles. The materials produce nano-droplet sized emulsions and the denaturing of 
protein and reduction of enzyme activity is not significant (Nesamony, J., et al. 2012). 
Optimization of the polymerizing procedure and material concentrations produce a 
nanoparticle size range appropriate for protein drug delivery. Sodium alginate, 
polymerization by the displacement of sodium ions with cross-linking calcium ions, is 
effective for the entrapment of β-glucuronidase that produces active microparticles 
(Burgess, D. J., and S. Ponsart. 1998).  The strongly polar property of alginate is a 
suitable environment for activity during entrapment in nanoparticles.  Active 
glucuronidase immobilization in nanoparticles is produced and an increase in activity, 
over standalone -glucuronidase, is shown in-vitro. Nanoparticle targeting strategies 
outlined, in Chapter IV, with the future directions sections of this paper complete the 
thesis.   
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CHAPTER 1 – INTRODUCTION 
 
I. Glucuronides as Prodrugs 
The Concept 
 Two decades ago “1992” in a Dutch lab a prodrug approach for the site-specific 
treatment of cancer was published by Haisma, H. J., E. Boven, M. van Muijen, J. de Jong, 
W. J. van der Vijgh, and H. M. Pinedo. The title “A Monoclonal Antibody-β-
Glucuronidase Conjugate as Activator of the Prodrug Epirubicin-Glucuronide for the 
Specific Treatment of Cancer” had the key concept that this thesis is based on. The 
glucuronide of an anti-cancer drug would reduce the toxicity of chemotherapy, utilizing 
site-specific activation. Epirubicin-glucuronide was chosen because of its stability and 
low cytotoxicity. When exposed to cancer cell lines A2780, MCF-7, and OVCAR-3; the 
cytotoxicity of epirubicin-glucuronide was at least 100 times less toxic than the parent 
drug epirubicin (Haisma, H., et al. 1992). This was attributed to reduced cellular uptake 
of the prodrug with (2.7 pmol/10 -6 cells/min) compared to the parent compound with 
(25 pmol/10^6 cells/min). Furthermore, epirubicin glucuronide was so stable in human 
blood and in cultured cancer cell lines that it was not converted into epirubicin, despite 
the presence of intracellular -glucuronidase (Hasima, H,. et al. 1992). The new problem 
was to find a way to increase activation and cellular uptake in-vivo at the target site.  
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This finding was critical to the fundamental principles of site-specific activation. If a 
glucuronide prodrug was activated by human glucuronidase in the liver and other tissues, 
the tumor site-specific activation would not be so specific. They used -glucuronidase 
from E.coli in a monoclonal antibody-enzyme conjugate that was able to activate the 
stable non-toxic prodrug epirubicin glucuronide at the tumor cell level. One problem with 
the use of bacterial glucuronidase was an immunogenic response to foreign proteins. 
Modifying human glucuronidase is one way this could be overcome. Another approach is 
to entrap copious amounts of bacterial glucuronidase within a porous, substrate 
diffusible, nanoparticle. The linking of one antibody to one enzyme, in this treatment, is 
limiting by the size of the activating area. A nanoparticle could act as a web of activity, 
providing a net for capturing and activating a prodrug that would result in smaller 
dosages and fewer side effects. (Hasima, H,. et al. 1992. "A Monoclonal Antibody-Beta-
Glucuronidase Conjugate as Activator of the Prodrug Epirubicin-Glucuronide for 
Specific Treatment of Cancer.") The effectiveness of this chemotherapy treatment may be 
greatly increased by immobilizing many -glucuronidase enzymes to each nanoparticle. 
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Overlooking Epirubicin  
Work by Pinedo and Haisma went in a direction away from epirubicin-glucuronide due to 
relatively slow cleavage rates. Other anthracycline-based glucuronides were cleaved at 
faster rates, namely doxorubicin. Over many years, they teamed up with Boven and Graff 
to enhance the activation by inserting various spacer molecules between doxorubicin and 
glucuronic acid to produce synthetic glucuronide prodrugs that were more efficiently 
hydrolyzed. DOX-mGA3 was the best and resulted in a 2.7 fold higher concentration of 
Doxorubicin in tumor tissue than DOX-GA3 (de Graff, M., et al. 2004). Although an 
improvement in activation, this ease of activation results in non-specific activation at 
non-cancerous -glucuronidase secreting cells.  
 
At the time, the most feasible way to improve glucuronide prodrug therapy was to 
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enhance cleavage and activation. Presently, with the use of nanotechnology, activation 
can be achieved by significantly increasing the amount of enzyme and the proximity of 
activation around the tumor, assuming that the prodrug will eventually be activated if it 
comes in contact with an antibody-targeted nanoparticle containing glucuronidase within 
it. In the past, epirubicin-glucuronide was explored and its low activation efficiency was 
found to be less desirable compared to other more easily cleavable anthracycline 
glucuronide prodrugs. This harder-to-activate prodrug would be ideal for site-specific 
activation by an embedded protected enzyme. The most important benefit is that 
epirubicin-glucuronide would also be less likely to be activated in non-cancerous tissues, 
reducing cardiotoxicity and other non-specific side effects. The issue now was weather 
the activation of the prodrug could be induced by targeting active glucuronidase to the 
tumor site. 
 
II. Enzyme Immobilized Nanoparticles as a Prodrug Activator 
Alginate Nanoparticles for Protein Delivery 
A nanoparticle is a bead-like, porous polymer with a diameter in the nanometer range. 
The size makes them useful for therapeutic drug and protein delivery. After researching 
numerous materials for drug and protein delivery, alginate was chosen as a suitable 
material for the encapsulated immobilization of β-glucuronidase. Because glucuronidase 
can activate a multitude of glucuronide-based prodrugs; β-Glucuronidase embedded 
nanoparticles, as prodrug activators, have enormous potential for site directed prodrug 
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therapy.  
 
The process of forming alginate nanoparticles relies on calcium ion induced cross-linking 
of alginic acid to form a lattice like structure around the material to be entrapped. A 
Water-in-oil emulsion technique was employed to produce the nano-droplet sized 
emulsions, called nanoemulsions. This occurs when the hydrophilic alginic acid and 
enzyme are mixed in a hydrophobic oil base to produce “bubbles” of the material to be 
polymerized. This sizing of particles, through nanoemulsions, is what results in 
nanoparticles of the corresponding diameter, based on the size of the “bubbles”. The oil 
phase, in the production of alginate nanoparticles, was chosen to be isopropyl myristate 
(IPM) along with an emulsifying agent of dioctyl sulfosuccinate sodium salt (DOSS). 
This idea came from a publication showing that entrapment of BSA protein in alginate 
nanoparticles, with DOSS-IPM, did not significantly degrade the protein (Nesamony, J., 
et al 2012).  
 
Alginate nanoparticles had previously been produced and loaded with another 
anthracycline named doxorubicin (Zhang, C., et al. 2011). This publication used a 
common EDC+NHS covalent binding method to bind a tumor-specific ligand for 
directing a nanoparticle to the target cancer site. The alginate was compatible with an 
anthracycline and allowed diffusion into and out of the particles. The production of the 
particles was performed followed by ligand attachment and then chemotherapeutic 
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anthracycline was loaded through dialysis and freeze drying. Once these robust 
nanoparticles are formed, they can be bonded with a multitude of ligands and loaded with 
a wide variety of drugs. This is contingent on material compatibility.           
           
          
 
 
III. Hypothesis and Aims 
The goal of this research was to develop a method that could produce enzyme-embedded 
nanoparticles, for site-specific anticancer prodrug activation. It may be possible to make 
nanodroplet sized emulsions, in the presence of a prodrug-activating enzyme, resulting in 
enzymatically active nanoparticles; under non-denaturing conditions without enzyme 
inhibiting materials and solvents. 
 
The two most common ways to add site-specific targeting to nanoparticles involves 
antibodies raised against an organ-specific receptor or using a tumor-selective antigen as 
the target. With these objectives in mind, a nanoparticle-based approach to chemotherapy 
could overcome many obstacles in the treatment of cancer, because local tumor 
concentrations of the activated drug moiety would be enhanced. A glucuronide prodrug 
(inactive) would be expected to have minimal off-target side effects.    
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The first goal was to research a suitable prodrug that could be converted to an active 
form, in the presence of an activating enzyme, for cancer treatment. One intriguing 
possibility was found in a pharmacological review titled “Enzyme-Catalyzed Activation 
of Anticancer Prodrugs” (Rooseboom, M., et al.). Page 83 of this review describes 
activation of a glucuronide-based prodrug by an E.coli β-glucuronidase enzyme (EC 
3.2.1.31). This review also states glucuronidated anthracycline type “prodrugs were 
developed to improve bioavailability and overcome the dose related cardiotoxicity of 
anthracyclines”. 
 
The second goal was to develop enzyme-embedded nanoparticles. A common route to the 
production of nanoparticles is to produce nanoemulsions with use of an emulsifier such 
as a surfactant. The general technique utilized was described as a water-in-oil 
nanoemulsion for the preparation of calcium alginate nanoparticles (Machado, A., et al. 
2012). Adaption of this procedure for our project was done with IPM as an enzyme-
compatible solvent, which allows for the phase inversion temperature method to be used 
as a way to produce nanoparticles under mild non-denaturing conditions. The analogous 
property of water allows it to expand just before its freezing point to allow an appropriate 
sized pocket for the formation of aqueous nanoparticles. An added benefit was that these 
refrigeration temperatures (2-6C) were likely to preserve the activity of the enzyme 
during polymerization.     
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Goal three was to develop a targeting method for directing the nanoparticles to a target 
tumor site. Various site-specific ligand and antibody conjugation concepts were 
referenced and considered. Although none were put into practice, some possibilities were 
identified.  
 
CHAPTER 2: PRODUCTION of GLUCURONIDES 
 
I. Glucuronidation of 4-Nitrophenol 
Background 
4-nitrophenol was used to determine the activity of glucuronide-forming enzymes, UDP-
glucuronsyltransferase (or UGT’s) within pig liver microsomes. Liver microsomes, a 
preperation of the endoplasmic reticulum obtained by differential centrifugation, are rich 
with a variety of drug metabolizing enzymes. UGT’s are the glucuronide transferring 
enzymes in the process known as glucuronidation (Remmel 2008). Pig liver microsomes 
were used to gain familiarity with the process of glucuronidation, in bio-organic 
synthesis. To determine the conditions required for a successful incubation, a 40 minute 
invitro microsomal incubation was performed in the presence of 1mM UDPGA. 
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Figure 2.1 (4-Nitrophenol Glucuronidation Reaction) 
 
Materials and Methods 
Materials 
Pig liver microsomes were obtained from the Remmel lab, UDPGA was ordered from 
SIGMA, as were Alamethicn, 4-Nitrophenol, TRIS hydrochloride and TRIS base from 
Malinckrodt, and Magnesium chloride from Malinckrodt (St. Louis, Mo). 
 
Incubation Conditions 
Every incubation mixture was in a total volume of 250μL. Typical conditions were made 
with concentrations from 5x stocks of all ingredients. In each 1.5mL test tube; 50μL of 
5mM UDPGA, 50μL of 250mM TRIS buffer (pH=7.4 at 37C), 50μL of 0.5mg/mL 
microsomal protein, 50μL of 25mM MgCl2, 45μL of substrate, and 5μL of Alamethicin 
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(20μg/mL). Alamethicin, a pore forming antibiotic is added to the microsomes to allow 
penetration of UDPGA into the lumen of the ER (UGT active site is on the inner face of 
the ER membrane). Protein or time was varied in subsequent experiments. 
 
 
 
 
Chromatographic Analysis of Glucuronide 
Following the incubation, the 250μL reaction mixtures were quenched with 250μL of ice 
cold acetonitrile and placed in an ice bath for 20 minutes. Then the 1.5mL test tubes 
(containing 500μL volume) were centrifuged at 13,000 g for 5 minutes, to remove 
precipitated protein. The top 250L was placed in an autosampler vial and run as a 
sequence on the Agilent 1100 HPLC.  
Chromatographic conditions of the 4-nitrophenol glucuronidation assay were optimized 
on an Agilent Zorbax SB-C8 4.6x250mm, 5micron column (Santa Clara, CA). The 
separation conditions were an isocratic elution with a 50/50 mix of acetonitrile and DI 
H2O at pH=6.7 with a flow rate of 1.1ml/min. A Shimadzu UV detector set at wavelength 
of 290nm detected 4-Nitrophenol at 3.78 minutes and its glucuronide at 1.74 minutes. 
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Figure 2.2 (4-Nitrophenol Representative Chromatograph) 
(Peak one is the more polar glucuronide and the second peak is 4-nitrophenol. In reverse 
phase chromatography, polar molecules elute first. ) 
 
4-Nitrophenol Standard Curve 
The chromatographic conditions were used to produce a standard curve for measuring 
glucuronide formation in the protein linearity and time dependence experiments.    
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Figure 2.3 (4-Nitrophenol and 4-Nitrophenyl Glucuronide Standard Curve of 
Millivolt Response to micromole Substrate Concentration)  
These conditions yielded over a 99% correlation coefficient when run in triplicate. The 
concentration of glucuronide formed can now be accurately quantified. 
 
Table 2.1 (4-Nitrophenol standard curve response in millivolts) 
PNP (uM) mV #1 mV #2 mV #3 
100 221790 219593 222768 
50 111878 109946 110234 
10 21374 22045 21849 
1 2423 2384 2281 
    
PNP (uM) S.D. C.V. AVG 
100 1626.03 0.73 221384 
50 1042.30 0.94 110686 
10 345.03 1.59 21756 
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1 73.36 3.10 2362 
    
PNG (uM) mV mV mV 
100 432785 424664 420380 
50 238744 230302 231266 
10 64565 54988 54664 
1 18518 17527 15924 
    
PNG (uM) S.D. C.V. AVG 
100 6300.63 1.48 425943 
50 4620.92 1.98 233437 
10 5625.15 9.69 58072 
1 1308.98 7.56 17323 
 
 
Protein Linearity of Microsomes with 100uM 4-Nitrophenol  
In a protein linearity experiment; protein concentrations of 0.05mg/mL, 0.1mg/mL, 
0.25mg/mL, and 0.5mg/ml were incubated for 10 minutes at 37 degrees celsius with a 
starting 4-nitrophenol concentration of 100M.  
     
Every incubation mixture was in a total volume of 250μL, Conditions were made with 
concentrations from 5x stocks of all ingredients. In each 1.5mL test tube; 50μL of 5mM 
UDPGA, 50μL of 250mM TRIS, 50μL of a 5x stock in mg/mL of microsomal protein, 
50μL of 25mM MgCl2, 45μL of substrate, and 5μL of Alamethicn (20μg/mL). 4-
Nitrophenol Glucuronide was measured by UV absorbance at 290nM wavelength. The  
formation was calculated in micromolar concentrations, determined from the standard 
curve absorbance.  
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Time Linearity of Microsomes with 100uM 4-Nitrophenol  
In linearity vs. time experiment 0.1mg/mL of protein was incubated, with 100M 4-
Nitrophenol, for times of 5, 10, 15, and 30 minutes.  
Every incubation mixture was in a total volume of 250μL, Conditions were made with 
concentrations from 5x stocks of all ingredients. In each 1.5mL test tube; 50μL of 5mM 
UDPGA, 50μL of 250mM TRIS, 50μL of 0.1mg/mL microsomal protein, 50μL of 25mM 
MgCl2, 45μL of substrate, and 5μL of alamethicin (1mg/ml stock) concentration 
(20μg/mL incubation concentration). 
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Results and Discussion 
 
 
 
Figure 2.4 (Plot of Para-Nitrophenyl Glucuronide vs. Total Microsomal protein) 
The figure (2.3) shows linearity with Glucuronidation of 100μM 4-Nitrophenol, at less 
than 0.1 mg/ml concentration of microsomal protein. 
Concentrations that maintain a constant metabolic turnover rate will indicate a linear 
range of protein suitable for metabolic turnover assays. Because the metabolizing 
enzymes are degraded during the incubation, the rate of turnover must be kept constant 
with the decreasing amounts of active enzyme. The slope or rate of turnover appears to 
remain constant at concentrations less than 0.1 mg/ml of microsomal protein. 
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Figure 2.5 (Time Dependent Linearity of Microsomal Glucuronidation with 100μM 
4-Nitrophenol) 
The linearity with time experiment showed repeated success in finding glucuronide 
forming incubation conditions. The linearity with glucuronidation of 100μM 4-
Nitrophenol occurs, within the first 10 minutes of incubation. 
These required concentration of 0.1 mg/ml of microsomal protein and incubation times of 
less than ten minutes were determined to be the constraints required for metabolic assays 
involving the glucuronidation of 4-nitrophenol. 
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Table 2.2 (Determination of Substrate and Product Concentrations after 
Incubation) 
 
Time 
(min) 
PNG formed 
(μM) #1 #2 #3 
0 0 0 0 
5 33.95 34.33 34.43 
10 59.45 57.64 57.52 
15 73.03 76.72 78.73 
30 98.72 99.77 100.32 
    
Time 
(min) PNG (AVG) S.D. C.V. 
0 0 0 0 
5 34.24 0.2532 0.7397 
10 58.20 1.081 1.858 
15 76.16 2.891 3.796 
30 99.60 0.8129 0.8162 
 
The coefficient of variation was held below 5%, for all timepoints. Following the 
linearity experiments of 4-nitrophenol, the potent anti-cancer drug Homoharringtonine 
(HHT) was obtained. Attempts to glucuronidate this drug, using the 4-nitrophenol-
incubation environment, became a priority for this project.  
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CHAPTER 2: PRODUCTION of GLUCURONIDES 
 
II. Attempted Production of HHT Glucuronide 
Background 
The drug HHT, also known as homoharringtonine, was chosen as a candidate for pro-
drug design because of its potent antitumor activity. (Hook, F., et al.). Glucuronidation is 
a common metabolic route for the detoxification and elimination of many xenobiotics. 
The production of a HHT Glucuronide had not been previously reported. An attempt of 
its synthesis was tried enzymatically and through organic synthesis.   
 
The synthetic route is typically more difficult and time consuming. If there are chances of 
letting the enzymes do all the work, it will likely have a higher product percentage yield 
while saving time. A direct line infusion on a thermo LC/MS/MS SRM mode for HHT-
glucuronide [M+H]+=722 with fragmentation to HHT [M+H]+=546 of the extracted 
incubation metabolites will be used, as an assay, to look for even trace amounts of the 
HHT glucuronide.  
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An enzymatic approach to the glucuronidation of HHT was carried out following a 
modified procedure from (Bioconjugate Chem. 2011, 22, 753-758 by Fan and Kharasch). 
This procedure was improved by using human liver microsomes (donated from the Tracy 
lab). Human liver microsomes are known to contain the greatest variety of UGT’s that 
can glucuronidate the greatest variety of xenobiotics. Therefore, these microsomes can 
offer the greatest chance for the successful glucuronidation of HHT. The enzymatic 
synthesis of HHT-β-D-glucuronic-acid was performed with variations of the 4-
nitrophenol glucuronidation procedure. A 100mM stock solution of HHT in DMSO was 
used to make a 0.1% concentration of DMSO in the incubation. This 100mM stock was 
the maximum amount soluble in DMSO and the diluted 100M incubation concentration 
was the maximum concentration possible for an uninhibited incubation (0.1% DMSO). 
 
The organic synthesis of HHT-β-D-Glucuronic-Acid was performed in three major steps. 
First, the addition of triacetylbromoglucuronic acid methyl ester to Homoharringtonine 
(HHT) was to be accomplished with silver carbonate as a catalyst. Second, the cleavage 
of the three-acetyl groups from the sugar moiety was time course tested with strong base. 
Third, removal of the methyl ester by hydride addition with product monitoring resulted 
in the loss of one or two acetyl groups. This procedure could also produce combinations 
of these three intermediate products in varying amounts.   
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Materials and Methods 
Materials 
Human liver microsomes were obtained from the Tracy lab, UDPGA was ordered from 
SIGMA, Alamethicn from SIGMA, Homoharringtonine from The Chinese Academy of 
Sciences, TRIS hydrochloride and TRIS base from SIGMA, Magnesium chloride from 
Malinckrodt, and Saccharic acid 1,4-lactone monohydrate from Fluka. 
 
Enzymatic Glucuronidation of HHT Incubation Conditions 
All ingredients used for the enzymatic reaction were prepared in 5x stocks. The total 
volume for the reaction mixture was 500μL in a 13mm x 100mm glass test tube. The total 
volume was 534μL after addition of the microsomes and 50 g of Alamethacin per 
milligram protein. First, 100μL of TRIS and 100μL of MgCl2 were added to the 13mm x 
100mm test tube. Four identical test tubes were placed in an ice bath with 17μL each of 
the Alamethacin (1mg/ml) and HLM protein (29.6 mg/ml) for 30min. The Alamethacin 
creates pores in the HLM to increase the accessibility of UDPGA for the UGT’s for 
acting on the substrate. Next, the four test tubes were moved to a 37°C water bath 
followed by the addition of 100μL of each remaining ingredient. The lactone preventing 
glucuronidase activity, the substrate HHT, and last UDPGA was added to initiate the 
reaction. The four samples were incubated for one hour and then the reaction was 
quenched with 500μL of ice-cold acetonitrile. Then the samples were placed in an ice 
bath for 30 minutes to allow the protein and salt to precipitate. Finally, the samples were 
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placed in 1.5ml flip cap tubes and centrifuged at 13,000 RCF for 5 minutes. The 
supernatant was saved in the freezer and an aliquot was loaded into an auto sampler vial 
for HPLC analysis. Table 2.4 lists the incubation conditions. 
 
Table 2.3 (HHT Incubation Conditions)  
HLM incubation ingredients 100μL of each 5x was used 
ingredients 5x conc. 1x conc.  
TRIS buffer pH=7.4 250mM 50mM  
Saccharic acid 1,4- lactone 25mM 5mM  
MgCl 25mM 5mM  
UDPGA 5mM 1mM  
HHT 500μM 100μM  
HLM protein 1mg/ml final 
conc. 
17μL (of 29.6mg/ml) added to the 500μL 
incubation 
Alamethacin 17ug/ml final 
conc. 
17μL (of 1mg/ml) added to the 500μL 
incubation 
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Analytical Methods for Enzymatic Incubation 
Direct line infusion into a Thermo quantum LC/MS/MS triple quadrapole mass 
spectrometer was used with Selective Reaction Monitoring to try and identify the 
transition of [M+H]+=722.6 with a 176 amu loss of glucuronide to [M+H]+=546.6 HHT. 
The positive mode electrospray ionization tandem mass spectrum failed to detect a 
MW=722 ion. HPLC fluorescence was also used for a separation of possible products 
approach, leading to molecule identification.  
 
An aqueous mobile phase of ammonium acetate and its conjugate base of acetic acid 
were prepared to a concentration of 25mM and mixed to provide a pH=4.7. Stationary 
phase used was methanol. These were run with a flow rate of 700μL/min in an isocratic 
method containing 65% MeOH, and pressure was 150bar. Separation was optimized on a 
Synergi Hydro reverse phase 80A measuring 250mm x 4.6mm, 4 micron. The detection 
was monitored with fluorescence at 280nm excitation and 320nm emission.    
 
 
 
Attempted Organic Synthesis of HHT Glucuronide Procedure 
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Following the procedure from (JOC v.69 #4,2004), the Koenigs-Knorr reaction was to be 
used as a method for the production of HHT glucuronide. The first step of this reaction 
uses AgCO3 as a catalyst to add the acetyl protected bromo sugar to the HHT substrate. 
This first step is illustrated below.  
  
 
 
 
 
 
 
 
 
 
 
 
Chemical Formula: C42H55NO18 
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Exact Mass: 861.34 
Molecular Weight: 861.88 
m/z: 861.34 (100.0%), 862.35 (46.7%), 863.35 (14.4%), 864.35 (3.3%) 
Elemental Analysis: C, 58.53; H, 6.43; N, 1.63; O, 33.41 
Figure 2.6 (Tri-Acetyl-Bromo-Glucuronic-Acid-Methyl-Ester Addition) 
 
Silver carbonate (0.25mmols) was added to 0.12mmol of HHT in a 0.1eq (0.12mmol / 
0.1eq = 1.2ml) of acetonitrile as a reaction solvent. The calculated concentrations for this 
first reaction are listed below in table 2.5. 
 
Table 2.4 (Organic reagents table) 
 HHT AgCO3 Bromo 
sugar 
Product 
expected 
MW 545.62 275.74 397.17 861.88 
Equivalents 1 2 3 1 
mmols 0.12 0.25 0.36 0.12 
Amount(mg) 68 69 147 107 
 
In a 10ml round bottom reaction vessel, containing 1.2ml of acetonitrile, 70mg of silver 
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carbonate were dissolved with rapid stirring. 70mg of HHT was then added to the silver 
carbonate/acetonitrile solution followed by 150mg of Aceto Bromo Glucuronic Acid 
Methyl Ester. While stirring at room temperature, the solution was brought to equilibrium 
over 48 hours until the green crystalline slurry turned to a dark mucky brown.  
 
The solution was poured into a filter funnel and vacuum filtered into a 50ml round 
bottom, washing with about 25ml of ethyl acetate. This removed the mostly insoluble 
silver catalyst from the solution, leaving a golden liquid. The golden reaction liquid was 
evaporated to dryness for 15 minutes on a Buchi rotary-evaporator, producing dark 
brown oil.  
 
Analytical Method for Organic Products (Normal Phase Chromatography) 
Normal phase conditions on silica TLC plates for analytical product separation were as 
follows. The oil-like product of this reaction was checked for reaction products by thin 
layer chromatography plating. The TLC plates were glass backed and silica coated and 
monitored under a broad UV spectrum. A spot of the reaction material was run with a 
spot of the starting material HHT and a spot of the bromo sugar. The conditions for 
separating the HHT from the reaction products were found to be 9 parts methylene 
chloride to 1 part methanol. These same conditions were used to separate products from 
starting material on a normal phase 25/40 size flash column filled with silica (4 angstrom 
in size). 24 test tubes containing about 10ml of solvent were collected.  
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Spot plating revealed two distinct spots with retention factors of Rf=0.3 and Rf=0.7. 
There was also a rich color running with the solvent line. The Rf=0.3 spot was identified 
as the starting material HHT, by co-spotting and comparison to a stock standard. The 
Rf=0.7 spot was to be identified by isolation of the material in the flash column.  
 
The flash column produced 24 fractions. The first 5 were clear, containing only solvent. 
Fractions 6-9 containing a rich yellow color, presumed to be the Rf=0.7 spot by TLC, 
were pooled for further analysis. Fractions 10 and 11 got clearer and showed no spot on 
TLC. Fractions 12-15 showed no spot by TLC, but were very reddish-yellow and were 
saved for further analysis by HPLC/Fluorescence. Fractions 17-22 were a light yellow 
and showed a spot by TLC that compared to the starting material HHT. Fractions 23-24 
were clear and showed no TLC spot, assuming only solvent was found and all organic 
material was previously eluted from the column. 
 
Fractions 12-15 were reddish-yellow and of much concern, because of the richness of the 
color, and were analyzed by HPLC/Fluorescence.  Further steps to characterize the three 
isolated pools, separated from the initial reaction mixture, were investigated by reverse 
phase liquid chromatography. Also, steps to recover the unreacted HHT from the pool of 
fractions 6-9 were employed.    
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Analytical Method (Reverse Phase Chromatography) 
 
In the previous section, the 1
st
 reaction step in the production of HHT glucuronide, 
normal phase flash column chromatography was used to produce fractions for the 
purification of possible reaction products. Combining three different ranges of fractions, 
three different pools were made. The first pool (fractions 6-9) showed a product spot on 
TLC where Rf=0.7. The second pool (fractions 12-15) showed no spot on TLC, but had a 
very rich reddish yellow color indicating the yellow HHT starting material may be 
present as an analog. The rotovaped second pool also produced red crystals. The third 
pool (fractions 17-22) showed a TLC spot with retention Rf=0.3 that compared to the 
starting material HHT. The presence of yellow material in pool two, along with the red 
crystals, encouraged the development of an analytical method, by HPLC/fluorescence, to 
confirm the presence or absence of a previously undetected HHT analog.  
 
The pooled fractions were evaporated to dryness in a Buchi rotary evaporator and each 
fraction was dissolved in approximately 10ml of methanol. One drop (20l), from each 
pool, was dissolved in an auto sampler vial containing approximately 2mL of methanol (a 
1:100 dilution). 10μL of each sample were injected onto an Agilent 1100 series HPLC. 
The method utilized fluorescence detection with an excitation at 280nm (the optimized 
wavelength for HHT) and emission at 320nm. Two distinct peaks were separated with 
retention times of 4.05min and 5.12min. The column had a void time of 2.35min, so these 
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compounds were adequately retained.  
 
An aqueous mobile phase of ammonium acetate and its conjugate base of acetic acid 
were prepared to a concentration of 25mM and mixed to provide a pH=4.7. Methanol was 
used as the organic modifier. These solvents were run at a flow rate of 700μL/min in an 
isocratic method at a ratio of 35:65 (65% MeOH), the column pressure was 150bar. 
Separation was optimized on a Synergi Hydro reverse phase 80A column measuring 
250mm x 4.6mm, 4 micron (Phenomenex Torrance, CA). The detection was monitored 
with fluorescence at 280nm excitation and 320nm emission.    
 
Results and Discussion of Identification of Organic Product Cephalotaxine 
The peak with retention time of 4.05min was identified as the starting material HHT. The 
third pool was now confirmed to be pure HHT recovered from the reaction. The second 
pool contained approximately a 50/50 mix of unreacted HHT and the unidentified peak at 
5.12min. The first pool contained at least 95% of the 5.12min unidentified peak.  
 
The 5.12min peak was collected to determine its mass. A mass of 743 was the most 
abundant and likely a decomposition product. My target mass of 863.9 was not seen, 
although the vast majority of unreacted HHT was recovered. The 4.05 minute peak had a 
mass of 316 and was identified as Cephalotaxine. This product resulted from cleavage of 
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the ester side chain of Homoharringtonine.   
 
The silver carbonate catalyzed Glucuronidation in acetonitrile failed to produce the 
desired product. Trace amounts of moisture may have contributed to an unsuccessful 
reaction. This can be compensated for with 4A molecular sieves, drying the glass, 
reacting under argon, and using an alternative dry solvent. This is outlined in 
(Bioconjugate Chem. 2011, 22, 753-758 by Fan and Kharasch) as “removal of any water 
produced is critical for the coupling reaction”. 
 
The same paper also outlines an enzymatic method of glucuronide production with three 
additional improvements over the method developed with 4-Nitrophenol. First, use 
saccharic acid lactone as a glucuronidase inhibitor because UGT enzymes from liver 
preparations naturally contain beta-glucuronidase. This would cause the enzymatic 
reaction to run in a futile cycle, if the UGT’s have poor activity with the substrate, 
glucuronidase may outcompete it. Second, aminobenzotriazole was added as a p450 
inhibitor. This will reduce or eliminate any competing metabolic pathways that are not 
UGT’s. Third, was the use of a NADPH generating system consisting of NADP+, 
glucose-6-phosphate, and glucose-6-phosphate dehydrogenase. These three 
improvements to an enzymatic incubation may be what is missing for a successful 
enzymatic glucuronidation procedure. Finally, human liver UGT’s generally contain 
more isoforms and act on a greater variety of xenobiotics.  
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CHAPTER 2 – PRODUCTION OF GLUCURONIDES 
 
III. Glucuronidation of Epirubicin 
Background 
The glucuronidation of epirubicin was performed to provide an anticancer glucuronide 
suitable for prodrug therapy. The design for the incubation conditions came from the 
publication identifying the glucuronidation enzyme as UGT2B7 (Innocenti, F., et al.).   
 
Materials and Methods 
Materials 
Human liver microsomes were obtained from BD Biosciences, UDPGA, Alamethicin, 
Epirubicin, TRIS hydrochloride and TRIS base were all obtained from SIGMA, and 
Magnesium chloride from Malinckrodt. 
 
Incubation Conditions for Epirubicin Glucuronide  
1.5 milliliter Eppendorf tubes contained 50μL each of, 5mg/ml microsomal protein, 
175uM Epirubicin (2% MeOH from the 1mg/ml methanolic stock), 250mM TRIS buffer 
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at pH=7.4, and 25mm MgCl2. The tubes containing the above ingredients were placed in 
an ice bath then 20μL of 1mg/ml alamethicin was added as a pore forming antibiotic to 
increase the bioavailability of UDPGA within the lumen of rectuloendoplasmic folds of 
the microsomes protein. This pore-forming antibiotic incubation was performed for 30 
minutes in an ice bath, before addition of UDPGA to start the reaction.  All samples were 
then removed from the ice bath and placed in a 37C shaking water bath incubator. After 
5 minutes the samples were at 37C and the glucuronidation reaction was initated by the 
addition of 50μL of 4mg/ml UDPGA (5mM). After 4 hours of incubation the majority of 
the epirubicin substrate was converted to its glucuronide at a rate of 5uM/hour. 
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Figure 2.7 (Epirubicin Before Microsomal Incubation) 
 
 
Figure 2.8 (Epirubicin After Microsomal Incubation) 
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Figure 2.9 (Epirubicin Glucuronide Formation)  
 
250μL of each epirubicin glucuronide containing incubation were loaded into a Millipore 
Centrifree 30,000 molecular weight cut-off protein filter to remove the microsomal 
protein and spun at 2000g for 20minutes. Then 200μL of each filtered sample was 
pipetted into a 1.5ml eppendorf tube and placed in a 37C shaking water bath for the 
confirmation and activation experiment. 
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Confirmation of Epirubicin Glucuronide in-vitro  
Conformation of epirubicin glucuronide formation was achieved by incubation with 
Epirubicin Glucuronide and E.coli origin β-glucuronidase. The 200L filtered samples at 
37C were ready for the hydrolysis confirmation experiment. The hydrolysis of the 
glucuronide was initiated by the addition of equal volume of glucuronidase (100U/ml) in 
4mM phosphate buffer pH=6.8. A time zero sample was taken by the removal of 100μL 
aliquot of the sample and placing it in 200μL of acetonitrile, vortexing, and placed in the 
fridge for 30 minutes. Time points at 1.5, 3, and 4 hours were taken the same way. Each 
sample time point was spun in a centrifuge at 13,000g for 5 minutes. 200μL of the 
supernatant were added to an autosampler vial and 40μL of each sample were injected 
onto the HPLC.  
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Figure 2.10 (Epirubicin Glucuronide Before Glucuronidase Addition) 
 
Figure 2.11 (Epirubicin Glucuronide After Glucuronidase Addition) 
HPLC Analytical conditions 
Mobile phase consisted of 40% A: 25mM ammonium acetate (1.9g Ammonium Acetate 
  36 
and 1.2mL Acetic Acid diluted to 1 Liter) and 60% B: Acetonitrile at a flow rate of 
1ml/min. The separation was achieved with an Agilent cyano (CN) column 250mm x 
4.6mm, 5 micron particle size.  
The retention times were 2.59 minutes for the glucuronide and 4.98 minutes for the 
substrate Epirubicin. The detection was by fluorescence ex=480 and em=560 with a gain 
of 100 on a Jasco fluorescent HPLC detector. 
 
Results and Discussion 
This procedure details the confirmation of the prodrug epirubicin glucuronic acid by the 
enzyme beta-glucuronidase.  Incubation conditions to produce the prodrug were 
implemented followed by the glucuronidase incubation conditions to revert the prodrug 
to its aglycone form. The goal of this experiment was to verify a robust assay for 
measuring the activity of beta glucuronidase-immobilized nanoparticles compared to 
non-immobilized glucuronidase protein in a rich human biological mimicking 
enviroment.   
The activation of the glucuronide prodrug (epirubicin) was achieved by converting most 
of the prodrug to the active form within 90 minutes of incubation. Average peak height, 
for the glucuronide, went from 85,000 millivolts response to 17,000 millivolts by the 90 
minute time point. 
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This assay provided a good test for confirmation of glucuronidase activity but the 
prodrug concentration is fixed at a starting concentration of 10uM. For further analysis of 
Epirubicin glucuronide, peaks were collected to produce a pure powder stock of the 
glucuronide. Collecting the peaks from an HPLC separation and drying under nitrogen 
provided a concentrate buffered in acetate. This was strong enough for a clean mass 
spectrum analysis, in an Ion-trap, mass spectrometer, and provided enough concentrated 
drug for invivo studies.  
The mass spectra from the fragmentation of larger ions were used to characterize 
Epirubicin and Epirubicin glucuronide. The mass data is presented in the subsequent 
figures. 
The fragmentation of these two molecules provided masses of 397.1 and 361.1 that were 
shared.  This further confirmed the production of the prodrug Epirubicin glucuronide. 
The mass of the epirubicin glucuronide protonated ion was reported to be MW=720.   
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Figure 2.12 (Epirubicin Fragmentation Pattern) 
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Figure 2.13 (Epirubicin Glucuronide Fragmentation Pattern) 
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CHAPTER 3: Nanoparticle Production 
 
I: Control of Alginate Nanoparticle Size with Emulsions 
Production of Alginate Gel Beads 
Background 
Alginate Gel Beads were synthesized by dropping an aqueous gel-like mixture containing 
sodium alginate, β-glucuronidase enzyme, and phosphate buffer (sol mixture), with a 
hypodermic needle, into a very strong solution of calcium chloride. This was an adaption 
of a yeast alcohol dehydrogenase immobilization in alginate gel beads procedure that 
utilized Sodium Alginate, YADH enzyme, and TRIS buffer; as the sol mixture (XU, S., 
et al. 2006)    
  
One goal was to make the non-micelle micro particles (gel beads) smaller. It was thought 
that by limiting the flow rate of the alginate enzyme infusion, into the calcium chloride 
polymerizing solution, with a slowly timed syringe pump; the droplet and resulting 
particle size would be significantly reduced. This was abandoned when no significant 
reduction in droplet size was observed. The physical property of producing an aqueous 
droplet may require formation under a strong vacuum and/or other difficult to replicate 
conditions, such as those observed during the electrospray ionization of mobile phase in a 
mass spectrum detector.  
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The final step was to attach the antibody onto the micelle formed nanoparticle as proof of 
concept that the alginates’ free carboxylate groups on the surface of the particle can be 
coupled with an antibody. I would do this through the Triazine promoted Amidation of 
carboxylic acids (Organic process & Development 1999, 3, 172-176 by Rayle and 
Fellmeth). 
 
Materials and Methods 
Materials 
Dioctyl sulfosuccinate sodium salt 98%, Sigma (DOSS) 
Isopropyl myristate 98%, Sigma (IPM) 
Alginic acid sodium salt 20,000-40,000cps viscosity, Sigma 
Calcium chloride dihydrate, Merck     
 
Materials Preparation Procedure for Microparticles 
A 2% PVA solution was made, by dissolving 1.2g of PVA in 60 ml deionized water. To 
help dissolve the PVA it was slowly added to the deionized water, in an ice bath, over 30 
minutes while stirring. Stirring continued for 2 more hours. Then, the PVA was 
microwaved for 15 seconds, cooled, and centrifuged at 1000 rpm for 10 minutes to 
remove the insoluble PVA. 
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1.5 mL of Alginic Acid Sodium Salt solution were prepared by dissolving 30mg in 1.5 
mL of deionized water while stirring for 2 hours. The alginate solution was then 
sonicated in an ice bath for 5 minutes. 
1000U of -glucuronidase were dissolved in 1.5 mL of deionized water and added to the 
1.5 mL alginate solution while stirring for 2 hours, vortex, and sonicated in an ice bath.  
6.5 mL of chloroform were used to dissolve 162.5mg of DOSS (2.5% solution). 
15 mL of deionized water were used to dissolve 11.9g of calcium chloride dihydrate to 
produce a 60% calcium solution. 
 
 
Microparticle Synthesis Procedure 
The preparation of a sodium alginate and DOSS (Dioctyl sulfosuccinate sodium salt, 98% 
Sigma) nanoparticles were produced by forming an emulsion of alginic acid and DOSS 
which was prepared in 2% polyvinyl alcohol. This emulsion was polymerized with 
calcium chloride. The particles were then washed three times and purified by 
centrifugation before freezing and lyophilizing.  
 
1 mL of each alginate solution was placed in a 15 mL tube. To this, 2 mL of the DOSS 
solution was added. This was vortexed and then sonicated in an ice bath with a sonicator 
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3000 at level 5 for 5 minutes to form an emulsion. 
The samples were poured into 50 mL tubes and 15 mL of the PVA solution were added. 
The samples were vortexed for 1 minute and then sonicated at level 5 for 5 minutes in an 
ice bath. 
Five ml of the 60% calcium chloride solution were added drop wise, over an hour, while 
stirring and left to stir overnight. 
To remove all traces of solvent the samples were stirred under vacuum for 1 hour in a 
cupped side arm flask. 
 
Wash and Purification Procedure for Microparticles 
The polymerized particles were placed in ultracentrifuge tubes and diluted to a 30ml total 
volume. These were spun at 35,000xg for 30 minutes. The supernatant was poured off 
and the particles dispersed in 5ml deionized water by sonication and then diluted to 
30mL. This was repeated 3 times. 
Removal of the aggregated particles from the nanoparticles was achieved by sonicating 
the particles then dispersing them in 10 mL of deionized water. The suspension was spun 
at 1000 rpm for 10 minutes and the supernatant was frozen at -80C for two hours before 
lyophilizing for 48 hours. 
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Solubility Points for Alginate Particles Sized by Emulsions 
To find the optimal ratio of a calcium chloride and an alginic acid microemulsion for 
nanoparticle synthesis, IPM was used in place of PVA (to make the particles smaller or to 
make the procedure simpler), different concentrations of Alginate were used while 
keeping the solvent and surfactant concentrations the same.   
 
The general technique utilized was described as a Water-in-Oil nanoemulsion for the 
preparation of calcium alginate nanoparticles (Machado, A., et al. 2012). This projects 
modification to this procedure was accomplished with IPM as an enzyme suitable 
solvent, but still retains the phase inversion temperature emulsification method. The 
Ostwald ripening phenomenon observed with 0.5%/W aginate compared favorably to 
peer results and observations (Machado, A. H., D. Lundberg, A. J. Ribeiro, F. J. Veiga, 
B. Lindman, M. G. Miguel, and U. Olsson. 2012.) A bimodal distribution of 
nanoparticles was observed to produce a distribution in the sub 1000nm particles size.    
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Nanoparticle Optimization Procedure 
Part1 
A 2% w/v solution of alginic acid was prepared in DI water. This was stirred overnight. 
Fifty l of this solution were added to 150μL of loading material (phosphate buffer 
pH=6.8 (4mM) and 1000U of -glucuronidase) to make a 0.5% alginic solution.  
A 0.2M DOSS in IPM solution was made by sonication for 2 hours. 
A 60% w/v solution of calcium chloride was prepared with its dihydrate requiring 
11.9g/15ml concentration. This was stirred overnight. The solution was diluted to a 0.6% 
w/v concentration. 
One part 0.6% CaCl2 was added to ten parts of the 0.2M DOSS/IPM, to form an emulsion 
by hand swirling. 
The 0.5% alginate solution was added in decreasing concentration by the addition of 
20μL of 0.5% algal to 200, 400, 600, 800, or 1000ul increments of the 0.2M DOSS/IPM. 
At the 20μL/1000ul concentration the algal solution did not crash out and its optimal ratio 
(maximum solubility) for an emulsion was found. 
Part2 
Two hundred microliters of the 0.054% CaCl2 micro emulsion were added to 1000μL of 
the 0.0098% alginic solution. 
This mixture was sonicated for 1.5 hours (hand swirling was also sufficient).  
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This resulted in 1.2ml of a double emulsion ultra-concentrate. 
Part 3 
Twenty l of the double emulsion concentrate were added to 10ml of water to form a 
suspension of 3 layers for the polymerization of nanoparticles by hydrophilic interaction 
in the aqueous layer. It is presumed the top layer is surfactant, the middle layer is the 
myristic oil, and the bottom layer is aqueous and rich with nanoparticles. 
 
Results and Discussion 
Previously a non-emulsion, a single emulsion with DOSS/chloroform, and a single 
emulsion technique with DOSS/IPM were used to produce nanoparticles with decreased 
size (respectively). This time a double emulsion technique was used to reduce the particle 
size during a hydrophillic polymerization of alginic acid with induced with calcium ions. 
This technique resulted in 25% 250nm particles and 70% 1 micron particles. The 
variation in size may be controlled with a syringe pump feeding into the calcium micro 
emulsion, the use of an ice water bath, and/or sonication during polymerization. This is 
an improvement over the previous method with the use of isopropyl myristate in place of 
chloroform, as an emulsion solvent, because the particle sizes were small and the solvent 
was less likely to denature the enzyme (Nesamony, J., et al.). 
 
This procedure successfully produced nanoparticles through an emulsification. More 
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diligent washing and a more consistent delivery of the calcium chloride, in the 
polymerization step, may improve the inconsistency in particle size. By using IPM over 
PVA the optimal solvent for alginate particle production was found (Nesamony, Shah, 
Kolling. 2012).  
 
This hydrophilic-induction polymerization procedure was successful and the solubility 
points for a double emulsion technique were explored. Dynamic light scatter revealed 
25% 250nm particles and 70% 1000nm particles. The technique and conditions were 
improved with this method to provide a smaller, more predictable, particle size. 
 
 
CHAPTER 3: Nanoparticle Production 
 
II. Mild Condition Protein Embedded Nanoparticle Production 
Background 
The effect of an ice cold water bath temperature during the polymerization of a calcium 
chloride and an alginic acid microemulsion for nanoparticle synthesis, with 0.2M DOSS 
in isopropyl myristate, was successful. So this was done with a high and low 
concentration of -glucuronidase. Further preparation of the nanoparticles was done by 
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centrifuging them at 3381g for 10minutes before measuring them with DLS (Nesamony, 
J., et al.). This was successful in removing impurities that could be interfering with the 
DLS measurement. 
 
Previously the double emulsion of calcium chloride and alginic acid was used to produce 
submicron nanoparticles. In the following procedure; High and low protein particles were 
made, one with 3.34mg in a 0.5% alginic solution, and another with 0.5mg in a 0.5% 
alginic solution.  
 
Materials and Methods 
Materials 
Dioctyl sulfosuccinate sodium salt 98%, Sigma (DOSS) 
Isopropyl myristate 98%, Sigma (IPM) 
Alginic acid sodium salt 20,000-40,000cps viscosity, Sigma 
Calcium chloride dihydrate, Merck      
 
Protein Immobilized Nanoparticles Procedure 
Part1 (material prep) 
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A 2% w/v solution of alginic acid was prepared in DI water. This was stirred overnight. 
Fifty l of this were added to 150μL of water containing 3.34mg of protein to make a 
0.5% alginic solution (high protein). Low protein particles were created with 0.5mg of 
protein in a 0.5% alginic solution. 
A 0.2M DOSS in IPM solution was made by sonication for 2 hours. 
A 60% w/v solution of calcium chloride was prepared with its dihydride requiring 
11.9g/15ml concentration. This was stirred overnight. The solution was diluted to a 0.6% 
w/v concentration. 
One part 0.6% CaCl2 was added to ten parts of the 0.2M DOSS/IPM, to form an emulsion 
by hand swirling, forming a 0.054% CaCl2 micro emulsion. 
Part2 (low protein) 
1000μL of 2% of the 0.5% alginic solution was prepared by adding 20μL of the 0.5% 
alginic solution to 1ml of DOSS/IPM. This formed a clear microemulsion. 
The 0.054% CaCl2 micro emulsion (200l) was added to 1000μL of the 0.0098% alginic 
solution with low protein (0.5mg). This was hand-swirled and resulted in 1.2ml of a 
double emulsion ultra-concentrate. 
The 1.2ml ultra-concentrate was added to a 500ml separation funnel followed by 500ml 
of ice cold DI water. This was shaken for 30 seconds and kept on ice for one hour. The 
particles were collected from the bottom layer and refrigerated overnight.  
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This gave a final calculated concentration of 1μg/ml  
Part 3 (high protein) 
Two hundred l of the 0.054% CaCl2 micro emulsion in AOT/IPM were added to 600μL 
of 0.2M DOSS/IPM comprised of 450μL of 0.2M DOSS/IPM and 150μL 0.5% alginic 
solution with 2.5mg of protein. This alginic solution was slightly cloudy. 
The resulting solution (800l) containing 2.5mg of protein was added to 6.7ml of ice cold 
DI water, swirled and placed in an ice bath for one hour, followed by refrigeration. 
This gave a final concentration of 0.334 mg/ml of total protein (calculated concentration). 
 
Results and Discussion 
1000U (based on phenolphthalein) high enzyme concentration and 150U low enzyme 
concentration particles were produced. The high protein condition produced 9.5 
milligrams of particles. 65% were 27 micrometer particles, 40% were 523 nanometer 
particles, and 5% were 33 nanometers. The low protein condition produced 14.5 
milligrams of particles. 65% were 70 micrometer particles, 4% were 3 micrometer 
particles, 30% were 277 nanometer particles, and 1% was 31 nanometer particles.   
 
These two methods used an ice bath to control the size of polymerization; coined phase 
inversion temperature emulsification method (PIT). The high protein conditions formed a 
  51 
suspension that was shaken just before the addition of water. The low protein conditions 
produced a clear single twin microemulsion.  
 
Both of these procedures used the Phase Inversion Temperature Method (PIT) to form a 
suspension of 3 layers for the polymerization of nanoparticles by hydrophilic interaction 
in the aqueous layer. It is presumed the top layer is surfactant, the middle layer is the 
myristic oil, and the bottom layer is aqueous and rich with, the highly polar, 
nanoparticles. 
 
 
 
 
 
 
 
Nanoparticles Images 
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Figure 3.1 (Particles are the Dark Spheres; Oil Droplets are the Light Spheres 
Image) 
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Figure 3.2 (Brownian Motion Movement of Particles Image) 
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CHAPTER 3: Nanoparticle Production 
 
III. Nanoparticle with Immobilized Protein; Characterization 
Background 
Beta-glucuronidase is an enzyme capable of cleaving the ester linkage of a glycolsidic 
bond. The amount of protein was characterized by a reverse biuret method of protein 
calibration. Two reagents were prepared following the Wang lab SOP. This procedure 
utilizes albumin as a standard for the calibration curve. The protein was characterized by 
the loss of absorbance, at 485nm, with increasing protein concentration. 
 
Materials and Methods 
Materials 
Beta-glucuronidase, bovine serum albumin, copper (II) sulfate pentahydrate, and 
bathocuproinedisulfonic acid disodium hydrate were purchased from Sigma-Aldrich. 
potassium sodium-tartrate tetrahydrate and ascorbic acid was purchased from 
Mallinckrodt. Sodium hydroxide was purchased from Fisher.  
 
Reagents A and B were prepared in in 25mL screw top jars. Reagent A contained: 
9.589μL of a CuSO4 (20% w/v) solution, 12.083mg potassium sodium-tartrate 
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tetrahydrate, 0.48mg NaOH, and de-ionized water to 20mL. Reagent B contained: 5mg 
ascorbic acid, 7.4mg bathocuproinedisulfonic acid, and de-ionized water to 20mL. The 
stock reagents were each vortexed and stored at room temperature. 
 
Dioctyl sulfosuccinate sodium salt 98%, Sigma (AOT); Isopropyl myristate 98%, Sigma 
(IPM); Alginic acid sodium salt 20,000-40,000cps viscosity, Sigma; Calcium chloride 
dihydrate, Merck; and -glucuronidase from E.coli (1000U/vial), Sigma in 4mM/10ml 
phosphate buffer  
 
 
 
Reverse Biuret Determination of Protein Concentration 
Bovine serum albumin was diluted to three concentrations for standard comparison. 
Concentrations of 1mg/mL, 0.5mg/mL, and 0.1mg/mL were prepared in de-ionized 
water. A 1000 unit vial of E.coli recombinant beta-glucuronidase, containing 4mM 
phosphate buffer (pH=6.8), was reconstituted with 10mL de-ionized water. The beta-
glucuronidase was used as three concentrations. Concentrations of 100%, 50%, and 10% 
were used as unknowns to be calculated from the albumin standards. 10μL of each of the 
six aforementioned protein samples were placed into their own 1.5mL reaction cuvette. A 
zero standard with 10μL of de-ionized water was added to a seventh cuvette. 200μL of 
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reagent A was added to each of the seven samples. These samples were mixed and 
incubated at 37°C for five min. Then 1000μL of reagent B were added and incubation 
continued for 0.5 min. The absorbance, at 485nm, was taken immediately after.  
 
 
    
Figure 3.1 (BSA Protein Calibration Chart) 
The reduction in absorbance of each sample, at 485nm, had a high correlation with the 
increase in protein levels of the sample. Figure 3.1 shows a regression coefficient of R
2
= 
0.99 with the known bovine serum albumin concentrations. The regression analysis 
produced a linear equation (Y= -0.135x + 0.765) and this was used to determine a 
334μg/mL stock concentration of β-Glucuronidase. Given a 10 ml volume, the vial 
contains 3.34 mg of protein 
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Table 3.1 Reverse Biuret Method of Protein Determination 
ABS(485nM) Sample Conc.  Calculated 
conc. 
Zeroed with DI 
H2O=0.1074 
0.7708 0 blank    
0.6339 1 1mg/ml BSA    
0.69 0.5 0.5mg/ml 
BSA 
   
0.7491 0.1 0.1mg/ml 
BSA 
 x=(ABS-
Yint)/slope 
0.7199 no dilution 10μL B-Gluc 0.334mg/ml (0.7199-0.765)/-
0.135 
0.746 50% of 
stock 
5μL B-Gluc 0.14mg/ml (0.746-0.765)/-
0.135 
0.7688 10% of 
stock 
1μL B-Gluc 0.028mg/mL 0.7688-0.765)/-
0.135 
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Glucuronidase Loaded Nanoparticles Loading Efficiency  
An emulsion (aqueous in oil), described below, was used to produce nanoparticles of 
225nm with a SD of 159nm in 90% abundance. -glucuronidase (2.5mg) was loaded into 
particles that polymerized in a 7.5ml total volume, yielding a potential of 334μg/ml GUS 
solution of particles in water. The emulsion (0.5ml) was centrifuged at 9000rpm and 
supernatant was assayed with equal volume Bradford reagent to show a 7.52μg/ml GUS 
concentration in the supernatant. The loading efficiency was determined to be 97.75% 
with a possible 3% variation. 
 
 
 
 
Optimized Method of nanoparticle production with Protein 
A 2% w/v solution of alginic acid was prepared in DI water. This was stirred overnight. 
50μL of this was added to 150μL of water, containing 3.34mg of protein material, to 
make a 0.5% alginic solution.  
A 0.2M DOSS in IPM solution was made by sonication for 2 hours. 
A 60% w/v solution of calcium chloride was prepared with its dihydride requiring 
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11.9g/15ml concentration. This was stirred overnight. The solution was diluted to a 0.6% 
w/v concentration. 
One part 0.6% CaCl2 was added to ten parts of the 0.2M DOSS/IPM, to form an emulsion 
by hand swirling, forming a 0.054% CaCl2 micro emulsion. 
200μL of the 0.054% CaCl2 micro emulsion in DOSS/IPM were added to 600μL of 0.2M 
DOSS/IPM comprised of 450μL of 0.2M DOSS/IPM and 150μL 0.5% alginic solution 
with 2.5mg of protein. This alginic solution was slightly cloudy. (3.34mgx0.75=2.505mg 
GUS) 
The 800μL solution containing 2.5mg of protein was added to 6.7ml of ice cold DI water, 
swirled and placed in an ice bath for one hour to induce PIT (phase inversion 
temperatures). 
This gave a final concentration of 0.334 mg/ml of total protein calculated concentration 
(2.505mg/7.5ml total liquid). 
A Bradford assay of the nanoparticles supernatant was needed to characterize the loading 
efficiency was done. This included spinning out the particles at 9000 rpm for 15 minutes 
and mixing 0.5ml of supernatant with 0.5ml of Bradford reagent at room temp for 10 
minutes. 
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y = 0.0268x + 0.0622
R² = 0.9942
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Figure 3.4 (Standard Curve of Protein Concentration) 
A standard curve was diluted from a stock of 334μg/ml (previously measured with the 
biuret assay) down to a range of 16.5μg/ml - 3.34μg/ml. 
 
 
 
Results and Discussion 
The unknowns and standards were run in triplicate to produce results with less than a 3% 
coefficient of variation. The regression equation was used to calculate a supernatant 
concentration of 7.52μg/ml GUS. 7.52488/334= 2.25%. This result was from a final 
concentration of 0.334 mg/ml of total protein calculated concentration (2.505mg/7.5ml 
total liquid). The loading efficiency was determined to be 97.75% with a possible 3% 
variation.  
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The activity of the particle will need to be tested. Fresh and 2 week old stored particles 
will be used to cleave p-nitro phenol glucuronide to p-nitro phenol. If this is successful, 
epirubicin glucuronide will be tested for cleavage and compared to pure GUS stock.  
 
Table 3.2 (Analysis of Variation in Protein Concentration Determination)  
Protein 
Concentration(μg/ml
) 
16.5 13.36 10.02 6.68 3.34 UKN 
485nm Absorbance 0.4813 0.4121 0.3454 0.2496 0.1355 0.2728 
485nm Absorbance 0.5057 0.4257 0.3406 0.2513 0.1419 0.2601 
485nm Absorbance 0.5010 0.4264 0.3429 0.2497 0.1403 0.2587 
Average 0.4960 0.4214 0.3429 0.2502 0.1392 0.2639 
SD 0.0129 0.0081 0.0024 0.000954 0.0033 0.0078 
CV 2.6100 1.9130 0.6999 0.3813 2.3921 2.9439 
 
 
CHAPTER 3: Nanoparticle Production 
IV: Enzyme Activity of Glucuronidase for Testing Embedded Nanoparticles 
Background 
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This assay resulted in a Vmax of 400umol/mg/min and a Km of 57.68uM. The previous 
method of producing nanoparticles, by a twin component single emulsion, had a loading 
efficiency of 97.8%. Next two-week old and freshly-prepared particles will be tested with 
4-nitrophenol glucuronide to look for cleavage to 4-nitrophenol. 4-nitrophenol has an 
absorbance max of 400nm. A spectrophotometric assay can now be employed to compare 
old and new particles kinetics with the 100U/ml stock solution. This spectrophotometric 
assay can be compared to the HPLC assay for the accuracy of the method. Upon success, 
an epirubicin glucuronide cleavage assay will be developed by a HPLC fluorescence 
method. 
 
Materials and Methods 
Materials 
β-Glucuronidase, Sigma; 4-Nitrophenyl-glucuronide, SIGMA; 4-Nitrophenol, SIGMA 
 
 
 
 
Methods of Protein Measurement 
A max absorbance of 400nm was found for 4-nitrophenol. Concentrations of 100, 50, 25, 
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15, and 5uM were each used with a 167μg/ml concentration of -glucuronidase to 
determine the kinetics for testing the -glucuronidase embedded nanoparticles. The total 
volume for the spectrophotometric assay was 1ml by diluting with DI water.  
 
The five concentrations were assayed and so was a standard curve. The slope in the first 
30 seconds of the assay was used to calculate the rate of 4-Nitrophenol formation for the 
5 concentrations. 
 
 
 
Glucuronidase Enzyme Activity after Nanoparticle Synthesis 
An optimization of the nanoparticle immobilization procedure was employed and activity 
was checked to ensure that the nanoparticle forming conditions would not denature the 
enzyme. There were three particle procedures tried. These procedures were previously 
described and tested for particle size. These are also provided below.  The goal in this 
round of production was to test for activity with 4-nitrophenyl-glucuronide as an 
indicator. Only the procedure described below resulted in enzyme activity, although 
losses in activity were too high and further work must be done to determine how much 
protein is in the particles and how much is in the surrounding solution. 
  64 
 
Method of Activity Detection 
A 2% w/v solution of alginic acid was prepared in DI water. This was stirred overnight. 
This solution was diluted 1:3 to a volume of 200l and contained 3.34mg of protein 
material to make a 0.5% alginic solution. These are the “high protein” nanoparticles. Low 
protein nanoparticles were created with 0.5mg of protein to make a 0.5% alginic solution. 
A 0.2M DOSS in IPM solution was made by sonication for 2 hours. 
A 60% w/v solution of calcium chloride was prepared with its dihydride requiring 
11.9g/15ml concentration. This was stirred overnight. The solution was diluted to a 0.6% 
w/v concentration. 
One part 0.6% CaCl2 was added to ten parts of the 0.2M DOSS/IPM, to form an emulsion 
by hand swirling, forming a 0.054% CaCl2 micro emulsion. 
After materials were prepped, the particle synthesis below was utilized  
200μL of the 0.054% CaCl2 micro emulsion in DOSS/IPM were added to 600μL of 0.2M 
DOSS/IPM comprised of 450μL of 0.2M DOSS/IPM and 150μL 0.5% alginic solution 
with 2.5mg of protein. This alginic solution was slightly cloudy. 
The 800μL solution containing 2.5mg of protein were added to 6.7ml of ice cold DI 
water, swirled and placed in an ice bath for one hour, followed by refrigeration. 
This gave a final concentration of 0.334 mg/ml of total protein calculated concentration. 
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In this procedure a suspension of 3 layers was formed for the polymerization of 
nanoparticles by hydrophilic-induction in the aqueous layer. It is presumed the top layer 
is surfactant, the middle layer is the myristic oil, and the bottom layer is aqueous and rich 
with nanoparticles. 
In order to quantify activity, a max absorbance of 400nm was found for 4-nitrophenol. 
Concentrations of 100, 50, 25, 15, and 5uM were each used with a 167μg/ml 
concentration of β-glucuronidase to determine the kinetics for testing the -glucuronidase 
embedded nanoparticles. The total volume for the spectrophotometric assay was 1ml by 
diluting with DI water. The five concentrations were assayed, by spectrophotometry, and 
a standard curve was made. 
 
Table 3.3 (Activity rates for β-Glucuronidase on 4-Nitrophenol) 
 
substrate 
conc 
(M) 
abs slope umol 
change 
stdabs abs is 
0.0084x 
umols/0.5
min 
rate/167g
protein 
100 0.76 0.36 42.8 0.7555 0.0063 21.45 128.3 
50 0.49 0.26 30.9 0.4859 0.0041 15.5 92.6 
25 0.32 0.17 20.1 0.319 0.0027 10.0 60.1 
15 0.23 0.12 14.2 0.2305 0.0019 7.12 42.6 
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5 0.091 0.04 5.27 0.0905 0.0007 2.64 15.8 
 
The activity of the particles, in the three procedures, was assayed and only the ultra-
concentrate had any activity at all. In fact, the activity was so high at 20μL/ml of ultra-
concentrate the slope was beyond the quantifiable range. Previously, 500μL of a 1000U 
or 1/20 of the stock was used (167μg protein). For this round, 20μL of a 100μL total 
volume was used for the assay, after particle production (167x4μg protein). This was to 
compensate for activity loss. 
 
Results and Discussion  
The standard curve was used to convert a change in absorbance into the umol rate of 
change. 
 
Figure 3.5 (Standard Curve for Micromole Rate of Change) 
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The Vmax and Km were determined were determined. First, a lineweaver-burke plot was 
made by ploting the inverse of the rate by the inverse of the substrate concentration.  
 
Figure 3.6 (Lineweaver-Burke Plot of Glucuronidase Activity) 
This was unsuccessful in determining the kinetics, as shown by the negative intercept. 
Next a Hanes-Woolf plot was made. These graphs were plotted from the data in the table 
below.  
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Table 3.4 (Micromole Change Rate and Substrate Concentration Kinetics)  
trial umolchange rate substrate 
conc(uM) 
s/v 1/v 1/s 
1 256.6 100 0.390 0.00390 0.01 
2 185.3 50 0.270 0.00540 0.02 
3 120.2 25 0.208 0.00832 0.04 
4 85.3 15 0.176 0.0117 0.067 
5 31.6 5 0.158 0.0317 0.2 
The Woolf plot was plotted using the substrate divided by the rate versus the substrate 
concentration. 
The rates were in umol/mg/min and the Vmax determined was also in micromoles.  
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Figure 3.7 (Hanes-Woolf Plot) 
In a Woolf plot, the inverse of the slope is the Vmax. So 
1/0.0025=400umol/mg/min=Vmax. The intercept is the Km/Vmax=0.1442. When the 
intercept is multiplied by the Vmax, the Km was obtained. 
The Km=57.68uM, this is low compared to the 200uM consensus Km from literature. I 
would need to use modeling software to get a better approximation, at these low 
concentrations.  
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CHAPTER 4: FUTURE DIRECTIONS 
Cancer Cell Model for Effectiveness of Prodrug Activating Nanoparticles 
To test the effectiveness of this alginate and enzyme complex to target cancer cells, an 
antibody and cancer cell model would be developed as follows. The Journal of Medicinal 
Chemistry 2008 article (Lu et al) outlines key integrins for anticancer targets with 
antibody, peptide, and nonpeptidic inhibitors. Inhibitors can be used to direct the 
nanoparticle to the target cancer receptor. Receptors are all variants of the vitronectin 
receptor. The more interesting variants include; AvB3, AvB5, A1B1, A5B1, and A2B1. 
Start by looking for a cell model that expresses either AvB3 or AvB5. This cell line must 
also be susceptible to epirubicin, such as breast cancer, GI cancers, or glioma’s. 
Alternative HHT considerations 
An antibody-targeted micro emulsion may be effective in targeted and controlled drug 
activation with release of HHT. Quick emulsion kits that are designed for antibody 
conjugated drug delivery are readily available (nofamerica.com sells them). They look 
very promising and repeatable. Successful delivery has been achieved with taxol-like 
compounds in micro-emulsions.   
Exploration of synthetic glucuronidation routes by addition of glucuronic acid to a side 
chain precursor for a bio-synthetic scheme or a total organic route of HHT-glucuronide 
synthesis. This would help characterize the ability of -glucuronidase from E.coli to 
cleave HHT-glucuronide. Other glucuronides of potent cytotoxins that could be evaluated 
are daunorubicin glucuronide or SN-38 glucuronide (SN-38 is the active phenolic 
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metabolite of the anticancer drug irinotecan).    
 
 
Design of HHT-Glucuronide Total Synthesis 
Various attempts to glucuronidate HHT via an enzymatic conjugation with glucuronic 
acid were unsuccessful. These unsuccessful reactions have led me to try an organic 
synthesis attempt at conjugating aceto-bromo-glucuronic acid methyl ester and HHT. 
This reaction only resulted in cleavage of the ester side chain. To further identify the 
chemical properties of HHT, glucuronidation of the ester side chain of HHT could be 
attempted. If addition of the protected glucuronic acid on to 6-Hydroxy-6-methyl-2-oxo-
heptanoic acid was successful, completion of side chain and addition to the core structure 
cephalotaxine would follow. If the addition is unsuccessful, it is reasonable to conclude 
glucuronidation of the HHT side chain may not be possible. 
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Fig. 4.1 (Reaction Scheme for Organic Synthesis of HHT-Glucuronide) 
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Method of Production 
The first step of the reaction, in the production of a glucuronic acid side chain of HHT, 
involves the addition of Aceto-Bromo-Glucuronic acid Methyl Ester with 6-Hydroxy-6-
methyl-2-Oxo-heptanoic acid. Figure 1.1 shows the overall reaction scheme.  
 
The Method of Production will include a reaction in THF. THF was chosen as a solvent 
because it is an aprotic solvent that is moderately polar. The reaction will consist of 1 
equivalent of the 6-Hydroxy-6-Methyl-2-Oxo-Heptanoic acid dissolved in THF. 2.2 
equivalents of lithium hydride base will be added through cannulation under nitrogen. 
The first proton to be abstracted will be the carboxylate followed by hydroxyl group. This 
makes the anionic hydroxyl group the most reactive site and the most likely to add the 
acetyl protected bromo glucuronic acid. One equivalent of acetyl bromo glucuronic acid 
and silver carbonate or silver triflate catalyst will be dissolved in THF and added to the 
Heptanoic acid and lithium hydride mixture through cannulation. This, in theory, should 
facilitate the addition of glucuronic acid to the ester side chain of HHT.    
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Results and Discussion:   
The results could be checked with Negative Electrospray ionization Tandem Mass Spec. 
This is ideal because of formation of the negative charge on the carboxylate end of the 
heptanoic acid glucuronate. 
 
The next step involves the addition of the Bromo acetate methyl ester through a Grignard 
reagent with magnesium catalyst. This would require 6 equivalents of lithium hydride to 
facilitate site specific addition at the 2 Oxo site of the heptanoic acid. 6 equivalents will 
be needed to simultaneously cleave the protecting acetyl groups and complete the side 
chain of HHT.    
 
The procedure is pretty straight forward but the 6-Hydroxy-6-Methyl -2-Oxo-Heptanoic 
acid needs to be synthesized. Because of the unavailability and difficulty in producing 6-
Hydroxy-6-Methyl -2-Oxo-Heptanoic acid, The Synthesis of HHT-Glucuronide was not 
implemented. 
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